NASDAQ:GBIO Generation Bio (GBIO) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free GBIO Stock Alerts $2.89 +0.04 (+1.40%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$2.83▼$3.1450-Day Range$1.97▼$4.3552-Week Range$0.86▼$6.98Volume78,483 shsAverage Volume269,841 shsMarket Capitalization$192.16 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Generation Bio alerts: Email Address Generation Bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside175.9% Upside$8.00 Price TargetShort InterestBearish3.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 starsMedical Sector470th out of 920 stocksPharmaceutical Preparations Industry204th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingGeneration Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneration Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.26% of the float of Generation Bio has been sold short.Short Interest Ratio / Days to CoverGeneration Bio has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Generation Bio has recently increased by 38.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeneration Bio does not currently pay a dividend.Dividend GrowthGeneration Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GBIO. Previous Next 1.7 News and Social Media Coverage News SentimentGeneration Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Generation Bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for GBIO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.22% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Generation Bio are expected to grow in the coming year, from ($1.34) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Generation Bio is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generation Bio is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneration Bio has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Generation Bio Stock (NASDAQ:GBIO)Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More GBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBIO Stock News HeadlinesApril 26, 2024 | americanbankingnews.comGeneration Bio Co. (NASDAQ:GBIO) Receives Average Rating of "Hold" from AnalystsApril 22, 2024 | globenewswire.comGeneration Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 2, 2024 | globenewswire.comGeneration Bio to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comGBIO May 2024 7.500 callMarch 16, 2024 | finance.yahoo.comGBIO Apr 2024 5.000 callMarch 8, 2024 | finance.yahoo.comGeneration Bio Co Reports Full Year and Q4 2023 Financial OutcomesMarch 7, 2024 | finanznachrichten.deGeneration Bio Co.: Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 6, 2024 | markets.businessinsider.comGBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comGeneration Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comGeneration Bio to Present at the 2024 TD Cowen Health Care ConferenceFebruary 25, 2024 | finance.yahoo.comGeneration Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth PlansFebruary 23, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO), Short Interest ReportFebruary 21, 2024 | investing.comGeneration Bio Co (GBIO)February 21, 2024 | msn.comWhat Is Biohacking And Why Gen Z And Millennials Are Obsessed With ItFebruary 6, 2024 | bizjournals.comGeneration Bio ends Waltham lease but landlord fights backFebruary 3, 2024 | msn.comGeneration Bio Co. Ends Lease Citing Landlord BreachJanuary 30, 2024 | msn.comThe booming business of discovering your biological age: This tech company will measure it starting at $400 per yearJanuary 19, 2024 | benzinga.comGeneration Bio Stock (NASDAQ:GBIO) Dividends: History, Yield and DatesJanuary 17, 2024 | entrepreneur.comGeneration Z: Page 4January 14, 2024 | msn.com42 Tiny Observations About Gen Z Culture That Will Be Seriously Enlightening To Other GenerationsJanuary 3, 2024 | finance.yahoo.comGeneration Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 7, 2023 | finance.yahoo.comCharles Rowland Bought 179% More Shares In Generation BioDecember 6, 2023 | finance.yahoo.comDirector Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)November 30, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)November 29, 2023 | msn.comGeneration Bio cuts its payroll by 40 percent in latest restructuring moveSee More Headlines Receive GBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/30/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GBIO CUSIPN/A CIK1733294 Webgenerationbio.com Phone617-655-7500FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+180.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,610,000.00 Net MarginsN/A Pretax Margin-2,144.51% Return on Equity-52.29% Return on Assets-31.80% Debt Debt-to-Equity RatioN/A Current Ratio6.83 Quick Ratio6.83 Sales & Book Value Annual Sales$5.90 million Price / Sales32.12 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book0.93Miscellaneous Outstanding Shares66,490,000Free Float52,659,000Market Cap$189.50 million OptionableOptionable Beta2.78 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Cameron Geoffrey McDonough M.D. (Age 54)President, CEO & Director Comp: $939.09kDr. Matthew Norkunas M.B.A. (Age 45)M.D., Chief Financial Officer Comp: $611.11kDr. Matthew Stanton Ph.D. (Age 50)Chief Scientific Officer Comp: $654.83kDr. Mark D. Angelino Ph.D. (Age 51)Co-Founder Dr. Robert Kotin Ph.D. (Age 68)Co-Founder Ms. Antoinette Paone M.B.A. (Age 45)M.S., Chief Operating Officer Ms. Yalonda Howze J.D. (Age 51)Chief Legal Officer & Secretary Ms. Jasmin TowerChief Human Resources OfficerDr. Phillip Samayoa Ph.D. (Age 36)Chief Strategy Officer More ExecutivesKey CompetitorsG1 TherapeuticsNASDAQ:GTHXMerrimack PharmaceuticalsNASDAQ:MACKFoghorn TherapeuticsNASDAQ:FHTXImmutepNASDAQ:IMMPPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCBought 105,827 shares on 4/5/2024Ownership: 0.574%PFM Health Sciences LPSold 891,956 shares on 2/15/2024Ownership: 2.455%Weiss Asset Management LPBought 81,630 shares on 2/12/2024Ownership: 0.124%Panagora Asset Management Inc.Bought 29,638 shares on 2/8/2024Ownership: 0.045%Los Angeles Capital Management LLCBought 209,462 shares on 2/6/2024Ownership: 0.417%View All Insider TransactionsView All Institutional Transactions GBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Generation Bio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBIO, but not buy additional shares or sell existing shares. View GBIO analyst ratings or view top-rated stocks. What is Generation Bio's stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for Generation Bio's shares. Their GBIO share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 175.9% from the stock's current price. View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts. How have GBIO shares performed in 2024? Generation Bio's stock was trading at $1.65 at the beginning of the year. Since then, GBIO shares have increased by 75.8% and is now trading at $2.90. View the best growth stocks for 2024 here. Are investors shorting Generation Bio? Generation Bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,580,000 shares, an increase of 38.6% from the March 31st total of 1,140,000 shares. Based on an average trading volume of 241,300 shares, the days-to-cover ratio is presently 6.5 days. Currently, 3.3% of the shares of the stock are sold short. View Generation Bio's Short Interest. When is Generation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our GBIO earnings forecast. How were Generation Bio's earnings last quarter? Generation Bio Co. (NASDAQ:GBIO) posted its earnings results on Wednesday, March, 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.12. The firm had revenue of $2.88 million for the quarter, compared to analyst estimates of $3.05 million. What other stocks do shareholders of Generation Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH). When did Generation Bio IPO? Generation Bio (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Generation Bio's major shareholders? Generation Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.57%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Dannielle Appelhans, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas. View institutional ownership trends. How do I buy shares of Generation Bio? Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GBIO) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generation Bio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
